FOFumihiko Ogata

Fumihiko Ogata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fumihiko Ogata has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Eiichiro Yamamoto

    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

    2 shared publications
  • Kenichi Tsujita

    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , Kumamoto

    2 shared publications
  • Satoshi Araki

    Department of General Medicine and Primary Care, Kumamoto University Hospital, Kumamoto University, Kumamoto, Japan

    2 shared publications
  • Shinsuke Hanatani

    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University

    2 shared publications
  • Yasuhiro Izumiya

    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

    2 shared publications
  • Yuichiro Arima

    Department of Anatomy, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

    2 shared publications

Latest Publications

  • Open Access

    IL-17A Mediates Cardiac Hypertrophy in Chronic Kidney Disease through the IL-23/Th17 Axis

    by Fumihiko Ogata, Shinsuke Hanatani, Yuki Okuno, Masahiro Yamamoto, Kei Morikawa, Takumi Nagakura, Satoshi Araki, Eiichiro Yamamoto, Yuichiro Arima, Yasuhiro Izumiya, et al.

    Background: Chronic kidney disease (CKD) is a major risk factor for cardiovascular morbidity, promoting left ventricular hypertrophy (LVH) prior to overt heart failure. The mechanisms underlying early cardiac remodeling in CKD remain incompletely understood. The IL-23/Th17/IL-17A inflammatory axis has emerged as a key mediator of cardiovascular pathology; however, its role in CKD-associated cardiac remodeling remains unclear. This study aimed to elucidate the contribution of this pathway to the early cardiac changes in CKD. Methods: Using a 5/6 nephrectomy (5/6Nx) mouse model of CKD, we evaluated cardiac structure, mitochondrial function, and inflammatory signaling. Cardiomyocyte transcriptomes were analyzed by RamDA-seq to identify molecular alterations. Circulating cytokines were profiled longitudinally, and IL-17A neutralization experiments were performed to assess causality. In addition, serum IL-12p40 concentrations were measured in patients with CKD and correlated with their renal function and cardiac remodeling indices. Results: At 16 weeks post-5/6Nx, mice developed LVH with preserved systolic function, accompanied by increased oxidative stress and mitochondrial structural abnormalities, but without significant myocardial fibrosis. Transcriptomic analysis identified oxidative phosphorylation as the most significantly downregulated pathway in cardiomyocytes. Despite increased mitochondrial DNA copy number and elevated PGC-1α expression, ATP production and mitochondrial respiratory chain proteins were reduced, indicating mitochondrial dysfunction. Circulating IL-12p40 and IL-23 levels increased progressively, concurrent with expansion of splenic Th17 cells and elevated cardiac IL-17A expression. Recombinant IL-17A directly impaired mitochondrial respiration in cultured cardiomyocytes. In vivo, IL-17A neutralization attenuated LVH, reduced oxidative stress, and partially restored mitochondrial protein expression without improving renal function. In patients with CKD, serum IL-12p40 levels correlated inversely with estimated glomerular filtration rate and positively with left ventricular mass index, supporting clinical relevance. Conclusions: Activation of the systemic IL-23/Th17/IL-17A axis contributes to early CKD-associated cardiac remodeling by promoting oxidative stress and mitochondrial dysfunction. Circulating IL-12p40 may serve as a biomarker of cardiorenal remodeling, and the IL-23/IL-17A pathway represents a potential therapeutic target. CLINICAL PERSPECTIVE: What Is New?: In a mouse model of chronic kidney disease (CKD), activation of the systemic IL-23/Th17/IL-17A axis was associated with left ventricular hypertrophy, oxidative stress, and mitochondrial dysfunction before the development of overt systolic dysfunction or myocardial fibrosis. In patients with CKD, circulating IL-12p40 levels were associated with both renal dysfunction and increased left ventricular mass. What Are the Clinical Implications?: These findings identify the IL-23/Th17/IL-17A axis as a potential mechanistic link between CKD and early cardiac remodeling, suggesting that inflammation may contribute to cardiac injury independently of worsening renal function. Targeting the IL-23/IL-17A pathway may represent a potential therapeutic strategy to prevent or attenuate CKD-associated cardiac remodeling before the development of overt heart failure.

  • Open Access

    Mild transverse aortic constriction and continuous aldosterone administration induce heart failure with preserved ejection fraction

    by Shinsuke Hanatani, Naoya Nakashima, Fumihiko Ogata, Masahiro Yamamoto, Yuki Okuno, Toshihiro Yamada, Satoru Yamamura, Satoshi Araki, Yuichiro Arima, Eiichiro Yamamoto, et al.


  • Open Access

    Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review

    by Shunsuke Mori, Fumihiko Ogata, Ryusuke Tsunoda

    Janus kinase (JAK) inhibitors have been developed as disease-modifying antirheumatic drugs. Despite the positive therapeutic impacts of JAK inhibitors, concerns have been raised regarding the risk of venous thromboembolism (VTE), such as deep vein thrombosis (DVT) and pulmonary embolism (PE). A recent post hoc safety analysis of placebo-controlled trials of JAK inhibitors in rheumatoid arthritis (RA) reported an imbalance in the incidence of VTE for a 4-mg daily dose of baricitinib versus placebo. In a recent postmarketing surveillance trial for RA, a significantly higher incidence of PE was reported in treatment with tofacitinib (10 mg twice daily) compared with tofacitinib 5 mg or tumor necrosis factor inhibitors. We also experienced a case of massive PE occurring 3 months after starting baricitinib (4 mg once daily) for multiple biologic-resistant RA. Nevertheless, the evidence to support the role of JAK inhibitors in VTE risk remains insufficient. There are a number of predisposing conditions and risk factors for VTE. In addition to the known risk factors that can provoke VTE, advanced age, obesity, diabetes mellitus, hypertension, hyperlipidemia, and smoking can also contribute to its development. Greater VTE risk is noted in patients with chronic inflammatory conditions, particularly RA patients with uncontrolled disease activity and any comorbidity. Prior to the initiation of JAK inhibitors, clinicians should consider both the number and strength of VTE risk factors for each patient. In addition, clinicians should advise patients to seek prompt medical help if they develop clinical signs and symptoms that suggest VTE/PE. Key Points• Patients with rheumatoid arthritis (RA) are at increased risk of venous thromboembolism (VTE), especially those with uncontrolled, high disease activity and those with comorbidities.• In addition to the well-known risk factors that provoke VTE events, advanced age and cardiovascular risk factors, such as obesity, diabetes mellitus, hypertension, hyperlipidemia, and smoking, should be considered risk factors for VTE.• Although a signal of VTE/pulmonary embolism (PE) risk with JAK inhibitors has been noted in RA patients who are already at high risk, the evidence is currently insufficient to support the increased risk of VTE during RA treatment with JAK inhibitors.• If there are no suitable alternatives, clinicians should prescribe JAK inhibitors with caution, considering both the strength of individual risk factors and the cumulative weight of all risk factors for each patient.